(secondQuint)A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years.

 For children age 2 years through 6 years, the recommended dosage schedule for intranasal administration is 0.

2 mL (0.

1 mL per nostril).

 For children not previously vaccinated against seasonal influenza, a second dose should be given after an interval of at least 4 weeks.

 For the safety and tolerability endpoint, data will be gathered on solicited symptoms, AEs and SAEs.

.

 A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years@highlight

This open-label, single arm, multicenter study will enroll approximately 100 subjects.

 The study is designed to gather the safety and tolerability data in Japanese children 2 to 6 years of age that would support approval of MEDI3250 in Japan.

